New Clinical Trial Shows COVID-19 Vaccines Rapidly Lose Effectiveness

A clinical trial funded by the National Institute of Allergy and Infectious Diseases shows that while COVID-19 vaccines initially enable the body to produce high levels of antibodies to the Omicron variant of SARS-CoV-2, this response decreases rapidly within 3 months. The trial included adults who had completed the initial recommended dosing schedule for any of the vaccines with Emergency Use Authorization from the United States Food and Drug Administration and who also had received a booster shot. The results suggest that a booster schedule to address emerging variants is needed. Click here to read more.